Bioventus Launches Durolane in the US

Bioventus launched DUROLANE single-injection hyaluronic acid (HA) product in the U.S. to treat joint pain associated with knee osteoarthritis (OA). The product joins Bioventus U.S. orthobiologic portfolio that includes three-injection HA GELSYN-3™ and five-injection HA SUPARTZ FX™. Bioventus is now the only orthobiologics company in the U.S....

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0